Citations

Showing 10 of 108104 citations.

Global prevalence and disease burden of vitamin D deficiency: a roadmap for action in low‐ and middle‐income countries
Roth, Daniel , Aloia, John F. , Bergeron, Gilles, Brown, Kenneth H. , Calvo, Mona S. , Combs, Gerald F., De‐Regil, Luz Maria , Jones, Kerry S. , Kapner, Hallie, Martineau, Adrian R. , Schleicher, Rosemary L. , Thacher, Tom D. , Whiting, Susan J. , Thacher, Thomas D , Abrams, Steven A. , Bourassa, Megan W. , Cashman, Kevin D. , Jefferds, Maria Elena , Neufeld, Lynnette Marie

Mayo Clinic

Annals of the New York Academy of Sciences | September 18, 2018 | Volume: 1430 | Issue: 1 | Pages: 44-79

10.1111/nyas.13968 | PMID 30225965 Get It

Abstract Vitamin D is an essential nutrient for bone health and may influence the risks of respiratory illness, adverse pregnancy outcomes, and chronic diseases of adulthood. Because many countries have a relatively low supply of foods rich in vitamin D and inadequate exposure to natural ultraviolet B (UVB) radiation from sunlight, an important proportion of the global population is at risk of vitamin D deficiency. There is general agreement that the minimum serum/plasma 25‐hydroxyvitamin D concentration (25(OH)D) that protects against vitamin D deficiency–related bone disease is approximately 30 nmol/L; therefore, this threshold is suitable to define vitamin D deficiency in population surveys. However, efforts to assess the vitamin D status of populations in low‐ and middle‐income countries have been hampered by limited availability of population‐representative 25(OH)D data, particularly among population subgroups most vulnerable to the skeletal and potential extraskeletal consequences of low vitamin D status, namely exclusively breastfed infants, children, adolescents, pregnant and lactating women, and the elderly. In the absence of 25(OH)D data, identification of communities that would benefit from public health interventions to improve vitamin D status may require proxy indicators of the population risk of vitamin D deficiency, such as the prevalence of rickets or metrics of usual UVB exposure. If a high prevalence of vitamin D deficiency is identified (>20% prevalence of 25(OH)D < 30 nmol/L) or the risk for vitamin D deficiency is determined to be high based on proxy indicators (e.g., prevalence of rickets >1%), food fortification and/or targeted vitamin D supplementation policies can be implemented to reduce the burden of vitamin D deficiency–related conditions in vulnerable populations.
Is Mild Asymptomatic Left Ventricular Systolic Dysfunction Always Predictive of Adverse Events in High-Risk Populations? Insights from the David-Berg Study
Redfield, Margaret M. , Calabrese, Alice, Canova, Paolo , Cioffi, Giovanni , Maria, Renata De , Grosu, Aurelia, Ferrari, Paola , Parati, Gianfranco , Gavazzi, Antonello , Gori, Mauro , Fontana, Alessandra , Iacovoni, Attilio , Senni, Michele

Mayo Clinic

European Journal of Heart Failure | September 18, 2018 | Volume: 20 | Issue: 11 | Pages: 1540-1548

10.1002/ejhf.1298 | PMID 30225956 Get It

Abstract Background Mild asymptomatic left ventricular systolic dysfunction (ALVSD) may be associated with incident heart failure (HF). However, this gray zone group needs incremental risk refinement. We hypothesized that diastolic dysfunction (DD) may refine HF and death risk prediction in mild ALVSD. Methods and results Among 4047 subjects aged ≥55/≤80 years followed by 10 general practitioners in northern Italy, the DAVID-Berg study prospectively enrolled 623 asymptomatic outpatients at increased risk for HF. Baseline evaluation included clinical visit, N-terminal pro B-type natriuretic peptide, and echocardiogram. Based on left ventricular ejection fraction (LVEF) and DD, subjects were classified as: control group (normal LVEF, n = 459, 76%), mild ALVSD (LVEF ≥40%/&lt;53%) without DD (n = 89, 15%) and with DD (n = 54, 9%). Subjects with LVEF &lt;40% or without full echocardiographic data were excluded from the analysis (n = 21). Mean age of the population was 69 ±7 years, 56% were men, mostly hypertensive, mean LVEF was 61%. During a median follow-up of 5.7 years, 88 subjects (15%) experienced HF/death events (59 HF events and 29 deaths). Compared to the control group, mild ALVSD was associated with a higher risk of incident HF/death (hazard ratio 1.80, 95% confidence interval 1.10–2.93, adjusted P = 0.019) according to the Cox proportional hazards model. However, this higher risk was present only in subjects with combined DD (P = 0.005) and not in those without it (P = 0.30). Results were consistent even considering the individual components of the primary outcome. Conclusion In a high-risk population, an echocardiographic exam is normally performed to assess systolic dysfunction. Our data underline the importance of also relying on DD to risk stratify mild ALVSD. Mild ALVSD might be a predictor of adverse events mainly in subjects with combined DD, though further studies are needed to confirm these results.
Population health challenges in primary care: What are the unfinished tasks and who should do them?
North, Frederick , Tulledge‐Scheitel, Sidna M. , Matulis, John C. , Pecina, Jennifer L. , Franqueira, Andrew , Johnson, Sarah S, Chaudhry, Rajeev , Franqueira, Andrew M, Pecina, Jennifer

Mayo Clinic

SAGE Open Medicine | September 18, 2018 | Volume: 6 | Issue: No issue available | Pages: No page available

10.1177/2050312118800209 | PMID 30245819 Get It

Background: There are numerous recommendations from expert sources that help guide primary care providers in cancer screening, infectious disease screening, metabolic screening, monitoring of drug levels, and chronic disease management. Little is known about the potential effort needed for a healthcare system to address these recommendations, or the patient effort needed to complete the recommendations. Methods: For 73 recommended population healthcare items, we examined each of 28,742 patients in a primary care internal medicine practice to determine whether they were up-to-date on recommended screening, immunizations, counseling, and chronic disease management goals. We used a rule-based software tool that queries the medical record for diagnoses, dates, laboratory values, pathology reports, and other information used in creating the individualized recommendations. We counted the number of uncompleted recommendations by age groups and examined the healthcare staff needed to address the recommendations and the potential patient effort needed to complete the recommendations. Results: For the 28,742 patients, there were 127,273 uncompleted recommendations identified for population health management (mean recommendations per patient 4.36, standard deviation of 2.65, range of 0–17 recommendations per patient). The age group with the most incomplete recommendations was age of 50–65 years with 5.5 recommendations per patient. The 18–35 years age group had the fewest incomplete recommendations with 2.6 per patient. Across all age groups, initiation of these recommendations required high-level input (physician, nurse practitioner, or physician’s assistant) in 28%. To completely adhere to recommended services, a 1000-patient cross-section cohort would require a total of 464 procedures and 1956 lab tests. Conclusion: Providers and patients face a daunting number of tasks necessary to meet guideline-generated recommendations. We will need new approaches to address the burgeoning numbers of uncompleted recommendations.
Heterogeneity in association of remote herpesvirus infections and pediatric MS
Rutatangwa, Alice , Waltz, Michael , Moodley, Manikum , Casper, T. Charles , Belman, Anita , Greenberg, Benjamin , Harris, Yolanda, Kahn, Ilana , Lotze, Timothy , Mar, Soe , Schreiner, Teri , Aaen, Gregory , Hart, Janace, Ness, Jayne , Rubin, Jennifer , Tillema, Jan‐Mendelt , Gorman, Mark , Rodriguez, Moses , Rose, John , Candee, Meghan , Shao, Xiaorong, Barcellos, Lisa F. , Rodriguez, Moses , Greenberg, Benjamin M , Nourbakhsh, Bardia , Rensel, Mary R. , Graves, Jennifer , Waldman, Amy , Goyal, Manu S. , Schreiner, Teri , Krupp, Lauren , Benson, Leslie, Chitnis, Tanuja , Weinstock‐Guttman, Bianca , James, Judith A. , Waubant, Emmanuelle L. , Edwards, Alice Rutatangwa , Rubin, Jennifer P

Mayo Clinic

Annals of Clinical and Translational Neurology | September 17, 2018 | Volume: 5 | Issue: 10 | Pages: 1222-1228

10.1002/acn3.636 | PMID 30349857 Get It

AbstractObjectiveWhile prior Epstein–Barr virus (EBV) infection has been consistently associated with subsequent risk of developing multiple sclerosis (MS), the association with other common herpesviruses has been more controversial. Our objectives were to determine whether remote infection with EBV and other common herpesviruses affect the susceptibility to pediatric MS and if there are interactions between genetic and demographic factors and viral infections.MethodsCases with pediatric‐onset MS or clinically isolated syndrome within 4 years of disease onset, and controls were recruited from 16 American pediatric MS centers. Logistic regression models adjusted for potential confounders assessed the association between case status and serological evidence for past infection with EBV, cytomegalovirus (CMV), Herpes Simplex viruses‐1 (HSV‐1) and ‐2. We determined the heterogeneity of the effect of viral infection on the risk of having MS according to race, ethnicity and HLA‐DRB1:1501 status.ResultsA total of 356 pediatric cases and 493 controls were recruited. In multivariable models, EBV‐viral capsid antigen (VCA) seropositivity was associated with increased odds of having MS by 7.4 times (95% CI: 4.5–12.0, P < 0.001). Seropositivity for HSV‐1 was also associated with increased odds of having MS (OR 1.54, 95% CI: 1.06–2.25, P = 0.025) but this increase was seen only in Whites (OR = 2.18, 95% CI 1.35–3.52, P < 0.001) and those negative for HLA‐DRB1*1501 (OR = 1.89, 95% CI 1.17–3.03, P = 0.009). The effect of remote EBV infection on the risk of pediatric MS depended on race and HLA‐DRB1*15:01 status.InterpretationEBV seropositivity is strongly associated with pediatric MS, as is HSV‐1 seropositivity in subjects negative for HLA‐DRB1*15:01. Our report of interactions between select viral exposures, and age, race and DRB1 status suggests a complex effect of environmental and genetic risk factors on MS development.
Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF
Washam, Jeffrey B. , Holmes, DaJuanicia N. , Thomas, Laine , Mahaffey, Kenneth W. , Kowey, Peter R. , Ansell, Jack , Go, Alan S. , Reiffel, James A. , Singer, Daniel E. , Blanco, Rosalia , Piccini, Jonathan P. , Pokorney, Sean D. , Hylek, Elaine M. , Fonarow, Gregg C. , Gersh, Bernard J. , Freeman, James V. , Naccarelli, Gerald V. , Peterson, Eric D.

Mayo Clinic

Journal of the American Heart Association | September 17, 2018 | Volume: 7 | Issue: 18 | Pages: No page available

10.1161/jaha.118.008928 | PMID 30371218 Get It

Background Chronic kidney disease ( CKD ) is a common comorbidity in patients with atrial fibrillation. The presence of CKD complicates drug selection for stroke prevention and rhythm control. Methods and Results Patients enrolled in ORBIT AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) with baseline renal function and follow‐up data were included (N=9019). CKD was defined as an estimated creatinine clearance <60 mL /min. Patient characteristics were compared by CKD status, and Cox proportional hazards modeling was used to examine the association between oral anticoagulant ( OAC ) use and outcomes and antiarrhythmic drug use and outcomes stratified by CKD stages. At enrollment, 3490 (39%) patients had an estimated creatinine clearance <60 mL /min. Patients with CKD were older and had higher CHA 2 DS 2 VAS c and Anticoagulant and Risk Factors in Atrial Fibrillation (ATRIA) scores. A rhythm control strategy was selected less frequently in patients with CKD , while OAC use was lower among Stage IV and V CKD patients. After adjustment, no significant interaction was noted for OAC and CKD on all‐cause mortality ( P =0.5442) or cardiovascular death ( P =0.1233), although a trend for increased major bleeding ( P =0.0608) and stroke, systemic embolism or transient ischemic attack ( P =0.0671) was observed. No interaction was noted for antiarrhythmic drug use and CKD status on all‐cause mortality ( P =0.9706), or stroke, systemic embolism or transient ischemic attack ( P =0.4218). Conclusions Patients with atrial fibrillation and CKD are less likely to be treated with rhythm control. Patients with advanced CKD are less likely to receive OAC . Finally, outcomes with OAC in patients with advanced CKD may be materially different with higher rates of both bleeding and stroke.
Concomitant Intra-Aortic Balloon Pump Use in Cardiogenic Shock Requiring Veno-Arterial Extracorporeal Membrane Oxygenation
Vallabhajosyula, Saraschandra , O’Horo, John C. , Antharam, Phanindra , Ananthaneni, Sindhura, Vallabhajosyula, Saarwaani , Stulak, John M., Eleid, Mackram F. , Rihal, Charanjit S. , Barsness, Gregory W. , Dunlay, Shannon M. , Vallabhajosyula, Saraschandra , O'Horo, John C , Gersh, Bernard J. , Rihal, Charanjit S.

Mayo Clinic

Circulation: Cardiovascular Interventions | September 17, 2018 | Volume: 11 | Issue: 9 | Pages: No page available

10.1161/circinterventions.118.006930 | PMID 30354593 Get It

Background: There are contrasting reports on the effectiveness of a concomitant intra-aortic balloon pump (IABP) in cardiogenic shock patients treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO). This study sought to compare short-term mortality in patients with cardiogenic shock treated with VA-ECMO with and without IABP. Methods and Results: We reviewed the published literature from 2000 to 2018 for studies evaluating adult patients requiring VA-ECMO for cardiogenic shock with concomitant IABP. Studies reporting short-term mortality were included. Meta-analysis of the association of IABP with mortality was performed using Mantel-Haenszel models. Subgroup analyses were performed in patients with cardiogenic shock complicating acute myocardial infarction (AMI) and postcardiotomy cardiogenic shock. Twenty-two observational studies with 4653 patients were included. These studies showed high heterogeneity for the total and postcardiotomy cardiogenic shock cohorts and low heterogeneity for the AMI cohort. Short-term mortality was not significantly different in patients with and without IABP 42.1% versus 57.8%; risk ratio, 0.80; 95% CI, 0.52–1.22; P =0.30. However, concomitant IABP with VA-ECMO was associated with lower mortality in patients with AMI (50.8% versus 62.4%; risk ratio, 0.56; 95% CI, 0.46–0.67; P <0.001). There was no difference in mortality in postcardiotomy cardiogenic shock and mixed causes for cardiogenic shock. Conclusions: In cardiogenic shock patients requiring VA-ECMO support, the use of IABP did not influence mortality in the total cohort. In patients with AMI, use of IABP with VA-ECMO was associated with 18.5% lower mortality in comparison to patients on VA-ECMO alone. Further randomized studies are warranted to corroborate these observational data.
Marantic Endocarditis Associated With T-Cell Large Granular Lymphocytic Leukemia: First Report of Its Occurrence With a Lymphoproliferative Malignancy in Adults
Jani, Prachi, Yamani, Mohamad H. , Alegria, Victoria R., Ailawadhi, Meghna, Ahmed, Salman , Ahmed, Salman , Ailawadhi, Sikander

Mayo Clinic

Journal of Oncology Practice | September 17, 2018 | Volume: 14 | Issue: 10 | Pages: 625-627

10.1200/jop.18.00168 | PMID 30222473 Get It

Granular cell astrocytoma: an aggressive IDH‐wildtype diffuse glioma with molecular genetic features of primary glioblastoma
Vizcaíno, M. Adelita , Palsgrove, Doreen N. , Yuan, Ming , Cabrera‐Aldana, Eibar Ernesto , Pallavajjala, Aparna, Burger, Peter C. , Rodríguez, Fausto J. , Rodriguez, Fausto J , Giannini, Caterina

Mayo Clinic

Brain Pathology | September 17, 2018 | Volume: 29 | Issue: 2 | Pages: 193-204

10.1111/bpa.12657 | PMID 30222900 Get It

AbstractGranular cell astrocytoma (GCA) is a rare adult infiltrating glioma subtype. We studied a series of 39 GCAs. Median age of presentation was 57.8 years and most cases developed in the frontal or temporal lobes. Tumors included grade II (n = 14), grade III (n = 11), and grade IV (n = 14) by WHO criteria. Granular cell morphology was diffuse in 31 (79%) cases and partial in eight (21%). Immunohistochemistry showed frequent positivity for GFAP (28 of 31), OLIG2 (16 of 16), and CD68 (27 of 30), but HAM56, CD163, and IBA‐1 histiocytic markers were all negative (22 of 22). IDH1(R132H) was negative in all the cases tested (16 of 16), while ATRX expression was retained (12 of 12). Cytogenetics demonstrated monosomy 10 (6 of 6) cases, +7 in 4 (of 6), −13q in 4 of 6, and −14 in 4 of 6. Next‐generation sequencing demonstrated mutations in PTEN/PIK3 genes in 6/13 (46%), NF1 in 3 of 10 (30%), TP53 in 3 of 13 (23%), PALB2 in 3 of 10 (30%), STAG2 in 3 of 10 (30%), EGFR mutation/amplification in 3 of 13 (23%), and AR in 2 of 10 (20%). CDKN2A/B deletion was identified in 5 of 13 (30%) cases (homozygous deletion in 4). The TERT C228T mutation was identified in 9 of 13 (69%). No mutations were encountered in IDH1, IDH2, CIC, FUBP1, H3F3A, BRAF or ATRX genes. The mean overall survival was 11.3 months. Patients >60 years old at diagnosis had a worse survival than patients <60 years (P = 0.001). There were no statistically significant differences in survival by WHO grade, extent of granular cell change, sex or MIB‐1 (P > 0.05). GCA is a variant of IDH‐wildtype diffuse glioma with aggressive behavior irrespective of grade and extent of granular cell morphology, and with molecular genetic features corresponding to primary glioblastoma.
Advances in multidisciplinary therapy for meningiomas
Brastianos, Priscilla K. , Butowski, Nicholas , Chan, Jason W., Dunn, Ian F. , Goldbrunner, Roland , Ippen, Franziska M. , Mawrin, Christian , Sloan, Andrew E. , Snyder, James , Tabatabai, Ghazaleh , Tatagiba, Marcos, Wen, Patrick Y. , Aldape, Kenneth, Nassiri, Farshad , Zadeh, Gelareh , Jenkinson, Michael D. , Raleigh, David R. , Au, Karolyn , Barnhartz-Sloan, Jill, Butowski, N, Carlotti, Carlos Gilberto , Griffith, Brent, Hashizume, Rintaro , Hanemann, C. Oliver , Huang, Raymond Y. , Jungk, Christine, Kaufman, Timothy J, Krischek, Boris , Lee, Ian , Liu, Jeff C. , Mamatjan, Yasin , Mansouri, Alireza , Ng, Ho‐Keung , Pirouzmand, Farhad , Poisson, Laila , Pollo, Bianca , Sahm, Felix , Saladino, Andrea , Santarius, Thomas , Schichor, Christian , Selman, Warren R., Spears, Julian , Suppiah, Suganth , Tatagiba, Marcos, Tirapelli, Daniela, Tsang, Derek S. , Vogelbaum, Michael A. , Deimling, Andreas von , Walbert, Tobias , Westphal, Manfred , Workewych, Adriana M , Tatagiba, Marcos , Galanis, Evanthia , Mansouri, Alireza , von Deimling, Andreas , Sahm, Felix , Huang, Raymond , Lee, Ian Y , Herold‐Mende, Christel C. , McDermott, Michael , Tatagiba, Marcos , Tonn, Joerg-Christian , Wen, Patrick Yung , Bi, Wenya Linda , Cusimano, Michael D. , DiMeco, Francesco , Drummond, Katharine Jann , Giannini, Caterina , Horbinski, Craig , James, David, Jungk, Christine, Lachance, Daniel Honore , Fougère, Christian la , Muñoz, David G. , Noushmehr, Houtan , Perry, Arie , Schultz, David , Schmidt, Nils Ole , Hanemann, C Oliver , Mamatjan, Yasin

Mayo Clinic

Neuro-Oncology | September 17, 2018 | Volume: 21 | Issue: Supplement_1 | Pages: i18-i31

10.1093/neuonc/noy136 | PMID 30649489 Get It